Mount Sinai First to Win All Three Major Scientific Achievement Awards from Crohn’s and Colitis Foundation of America
For the first time ever, three researchers from The Mount Sinai Hospital have won all the scientific achievement awards from the Crohn’s & Colitis Foundation of America in a single year.
“This is the first time in the history of the award that all three winners are from the same medical institution,” said Marjorie Merrick, Vice President of Research Special Projects at Crohn’s & Colitis Foundation of America. “And it seems quite fitting that they all are from Mount Sinai, where Crohn’s disease was first described by Dr. Burrill B. Crohn, a Mount Sinai physician, and where groundbreaking research and treatment for Crohn’s continues today.”
“We are absolutely delighted that the CCFA has chosen to recognize our Mount Sinai colleagues, Drs. Sachar, Cho and Colombel, for their outstanding contributions, innovation and leadership in IBD,” said Bruce Sands, MD, Dr. Burrill B. Crohn Professor of Medicine and Chief of the Dr. Henry D. Janowitz Division of Gastroenterology in the Samuel Bronfman Department of Medicine at Icahn School of Medicine at Mount Sinai. “These awards recognize not only their profound individual contributions to this area, but also Mount Sinai’s ongoing contributions to understanding these complex and difficult diseases.”
Dr. Burrill Crohn, for whom the disease was named after, practiced at The Mount Sinai Hospital. In 1967 the Crohn’s & Colitis Foundation of America was started at Mount Sinai by then GI Division Chief Henry D. Janowitz, MD, Bill and Shelby Modell, and Suzanne and Irwin Rosenthal. After Dr. Janowitz’s passing, the Crohn’s & Colitis Foundation of America established the Henry D. Janowitz Lifetime Achievement Award in IBD in his honor.
Members of the medical and scientific community are invited to nominate outstanding physicians and scientists for this award and the CCFA Scientific Achievement Awards in both Clinical and Basic Research. Winners are chosen by a blinded panel of members of CCFA’s National Scientific Advisory Committee. The awards ceremony will take place during CCFA’s annual Advances in Inflammatory Bowel Diseases Conference, held from December 04 - 06 in Orlando, Flordia.
The winners of the 2014 Scientific Achievement Awards are:
• Henry D. Janowitz Lifetime Achievement Award in IBD:
DAVID B. SACHAR, MD, Clinical Professor of Medicine at the Icahn School of Medicine and Director Emeritus of the Dr. Henry D. Janowitz Division of Gastroenterology in the Samuel Bronfman Department of Medicine at the Icahn School of Medicine at Mount Sinai.
Dr. Sachar was the first Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine from 1992-1999. Dr. Sachar also held served as chairman of the Samuel Bronfman Department of Medicine and Director of the Dr. Henry D. Janowitz Division of Gastroenterology at The Mount Sinai Hospital (1983-99).
He was the first American elected Chairman of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD). From 2005-2008 Dr. Sachar served as Chairman of the GI Advisory Panel of the FDA.
As a professor, he has earned 1996 Distinguished Educator Award of the AGA, the 2005 Berk/Fise Clinical Achievement Award of the ACG for “an entire career of service to patients and fellow practitioners,” and a dozen other national and international awards. To date he has published more than 260 articles on the topic of IBD.
• Scientific Achievement in IBD Clinical Research:
JEAN-FRÉDÉRIC COLOMBEL, MD, Professor of Medicine and Director of The Leona M. and Harry B. Helmsley Charitable Trust inflammatory Bowel Disease Center at Icahn School of Medicine at Mount Sinai.
Dr. Jean-Frédéric Colombel is Professor of Medicine and past-president of ECCO (European Crohn’s and Colitis Organization) and a past-chair of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD).
He is the associate editor of Alimentary Pharmacology Therapy, and serves as an editorial board member or a reviewer for several journals including Gut, Journal of Crohn’s and Colitis, and Nature Reviews in Gastroenterology and Hepatology. He is the author or co-author of more than 600 published articles and books.
• Scientific Achievement in Basic IBD Research:
JUDY H. CHO, MD, Ward-Coleman Professor of Translational Genetics and Medicine, Vice-Chair of Translational Genetics, Associate Chief for Research in the Dr. Henry D. Janowitz Division of Gastroenterology and Director of CePORTED at the Icahn School of Medicine at Mount Sinai.
As the first woman to win this award, she is the principal investigator and chair of the Steering Committee of the NIH’s National Institute for Diabetes and Digestive and Kidney Diseases IBD Genetics Consortium.
Dr. Cho has served on the NIDDK Council, the Council for the American Society of Clinical Investigation (ASCI) and is a member of the American Association of Physicians (AAP). She led efforts in identifying NOD2, one of the first genes associated with Crohn’s disease. She has also led efforts in identifying associations of 163 genetic loci to IBD. Her laboratory is presently investigating the role of less common genetic variations contributing to IBD in the Ashkenazi Jewish population.
“On behalf of the millions of IBD patients worldwide, we extend heartfelt congratulations and thanks to these winners for their courage, innovation and vision as leaders in the IBD scientific community,” said CCFA’s Chief Scientific Officer Caren Heller, MD, MBA. “Their significant efforts have moved IBD research and patient care in directions that ultimately improve the quality of life for patients of all ages and their families.”
About CCFA
The Crohn's & Colitis Foundation of America (CCFA) is the largest voluntary non-profit health organization dedicated to finding cures for Inflammatory Bowel Diseases (IBD). CCFA’s mission is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults who suffer from these diseases. The Foundation works to fulfill its mission by funding research, providing educational resources for patients and their families, medical professionals, and the public, and furnishing supportive services for those afflicted with IBD. For more information, visit www.ccfa.org, call 888-694-8872, like us on Facebook, find us on LinkedIn or follow us on Twitter.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.
Drug Resistance Signature Discovered in Crohn’s Disease
Aug 29, 2019 View All Press ReleasesMount Sinai Health System Launches Collaboration With the Regeneron Genetics Center
Nov 09, 2016 View All Press Releases